Cargando…

Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma

Fifteen patients with relapsed osteosarcoma were treated with an intensive combination chemotherapy schedule. Ifosfamide 2.5 g m(−2) daily and etoposide 150 mg m(−2) daily coincidentally for 3 days and high-dose methotrexate 8 g m(−2) (with folinic acid rescue) on days 10–14 in a planned 21-day cycl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michelagnoli, M P, Lewis, I J, Gattamaneni, H R, Bailey, C C, Lashford, L S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362262/ https://www.ncbi.nlm.nih.gov/pubmed/10098754 http://dx.doi.org/10.1038/sj.bjc.6690187

Ejemplares similares

Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing’s and other Small Round Cell Sarcomas
por: Whelan, Jeremy, et al.
Publicado: (2012)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
por: Tay, Tricia, et al.
Publicado: (2022)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study
por: Scinto, A F, et al.
Publicado: (1999)

Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease
por: Dobson, L S, et al.
Publicado: (2000)

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
por: Rezaï, Keyvan, et al.
Publicado: (2007)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
por: Mitry, E, et al.
Publicado: (1999)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females
por: Zanetta, G, et al.
Publicado: (1999)

Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia
por: Aminimoghaddam, Soheila, et al.
Publicado: (2018)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
por: Mahdy, Ahmed, et al.
Publicado: (2023)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis
por: Fan, Xiao-Liang, et al.
Publicado: (2015)

Intra-patient dose escalation in Ewing’s sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review
por: Lewin, Jeremy, et al.
Publicado: (2013)

Valsalva-Like Retinopathy Secondary to Pancytopenia following Induction of Etoposide and Ifosfamide
por: Prinzi, Robert A., et al.
Publicado: (2015)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Combination of ifosfamide and etoposide as a salvage regimen for previously treated soft tissue sarcomas: a retrospective single centre study
por: Ribeiro, Luiz Fernando, et al.
Publicado: (2022)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis
por: Saito, Shiro, et al.
Publicado: (2020)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Cancer
por: Kang, Heeseok, et al.
Publicado: (2009)

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
por: Zhou, Ping, et al.
Publicado: (2015)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Kim, Hyun Jee, et al.
Publicado: (2018)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile
por: Banh, Cindy, et al.
Publicado: (2021)

The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
por: Zhang, Bin, et al.
Publicado: (2020)

Paclitaxel–ifosfamide–carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours
por: Kosmas, C, et al.
Publicado: (2011)

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
por: Thatcher, N., et al.
Publicado: (1989)

Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours
por: Anthoney, D A, et al.
Publicado: (2004)

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
por: Bleehen, N. M., et al.
Publicado: (1993)

Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study
por: Mi, Mi, et al.
Publicado: (2020)

Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide
por: Kanno, Toshiyuki, et al.
Publicado: (2018)

Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation
por: Yu, Dapeng, et al.
Publicado: (2019)

Nomogram predicting leukopenia in osteosarcoma after high-dose methotrexate chemotherapy
por: Wu, Haixiao, et al.
Publicado: (2022)

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
por: Bleehen, N. M., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_opdulk6ckq950lm5ukglbnfcvf